Literature DB >> 2767711

Increased sensitivity of the chemoattractant-induced chemiluminescence in eosinophils isolated from atopic individuals.

L Koenderman1, P L Bruijnzeel.   

Abstract

Eosinophilia in peripheral blood is a common phenomenon associated with atopic condition. The present study illustrates the enhanced sensitivity of these eosinophils for formyl-methionyl-leucylphenylalanine (FMLP) and platelet-activating-factor (PAF) (measured as luminol-enhanced chemiluminescence) compared with eosinophils isolated from the peripheral blood of normal individuals. The PAF-induced chemiluminescence, which is peroxidase dependent and of extracellular origin, is inhibited by the PAF antagonist BN52021. The enhanced sensitivity of eosinophils isolated from atopic patients for FMLP and PAF might reflect a 'primed' state of these cells, relevant for the pathogenesis of atopic disease.

Entities:  

Mesh：

Substances：

Year:  1989        PMID： 2767711      PMCID： PMC1385327     

Source DB:  PubMed          Journal:  Immunology        ISSN： 0019-2805            Impact factor:   7.397


  12 in total

1.  An improved method for the isolation of eosinophilic granulocytes from peripheral blood of normal individuals.

Authors:  L Koenderman; P T Kok; M L Hamelink; A J Verhoeven; P L Bruijnzeel
Journal:  J Leukoc Biol       Date:  1988-08       Impact factor: 4.962

2.  The role of the eosinophilic leukocyte in bronchial asthma.

Authors:  G G Gleich
Journal:  Bull Eur Physiopathol Respir       Date:  1986

3.  Mechanism of the luminol-dependent chemiluminescence of human neutrophils.

Authors:  L R DeChatelet; G D Long; P S Shirley; D A Bass; M J Thomas; F W Henderson; M S Cohen
Journal:  J Immunol       Date:  1982-10       Impact factor: 5.422

4.  Bronchoalveolar eosinophilia during allergen-induced late asthmatic reactions.

Authors:  J G De Monchy; H F Kauffman; P Venge; G H Koëter; H M Jansen; H J Sluiter; K De Vries
Journal:  Am Rev Respir Dis       Date:  1985-03

5.  Specific leukotriene formation by purified human eosinophils and neutrophils.

Authors:  J Verhagen; P L Bruynzeel; J A Koedam; G A Wassink; M de Boer; G K Terpstra; J Kreukniet; G A Veldink; J F Vliegenthart
Journal:  FEBS Lett       Date:  1984-03-12       Impact factor: 4.124

6.  Intra- and extracellular events in luminol-dependent chemiluminescence of polymorphonuclear leukocytes.

Authors:  G Briheim; O Stendahl; C Dahlgren
Journal:  Infect Immun       Date:  1984-07       Impact factor: 3.441

7.  Heterogeneity of human peripheral blood eosinophils: variability in cell density and cytotoxic ability in relation to the level and the origin of hypereosinophilia.

Authors:  L Prin; M Capron; A B Tonnel; O Bletry; A Capron
Journal:  Int Arch Allergy Appl Immunol       Date:  1983

8.  Metabolic heterogeneity of eosinophils from normal and hypereosinophilic patients.

Authors:  S H Pincus; W R Schooley; A M DiNapoli; S Broder
Journal:  Blood       Date:  1981-12       Impact factor: 22.113

9.  Some properties of human eosinophil peroxidase, a comparison with other peroxidases.

Authors:  B G Bolscher; H Plat; R Wever
Journal:  Biochim Biophys Acta       Date:  1984-01-31

10.  Human eosinophil peroxidase: purification and characterization.

Authors:  M G Carlson; C G Peterson; P Venge
Journal:  J Immunol       Date:  1985-03       Impact factor: 5.422
View more
  2 in total

Review 1.  PAF. A review of its effects, antagonists and possible future clinical implications (Part II).

Authors:  M Koltai; D Hosford; P Guinot; A Esanu; P Braquet
Journal:  Drugs       Date:  1991-08       Impact factor: 9.546

2.  C3a is a chemotaxin for human eosinophils but not for neutrophils. I. C3a stimulation of neutrophils is secondary to eosinophil activation.

Authors:  P J Daffern; P H Pfeifer; J A Ember; T E Hugli
Journal:  J Exp Med       Date:  1995-06-01       Impact factor: 14.307
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.